These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8002061

  • 1. Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules.
    Silva IN, Oliveira-Júnior DF, Simal CJ, Viana MB, Chagas AJ.
    Indian J Pediatr; 1994; 61(4):341-6. PubMed ID: 8002061
    [Abstract] [Full Text] [Related]

  • 2. Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia.
    Winterer J, Chrousos GP, Loriaux DL, Cutler GB.
    J Pediatr; 1985 Jan; 106(1):137-42. PubMed ID: 3871229
    [Abstract] [Full Text] [Related]

  • 3. [Value of the assay of plasma steroids in the control of congenital adrenal hyperplasia].
    Theintz GE, Sizonenko PC.
    Arch Fr Pediatr; 1985 Mar; 42(3):211-7. PubMed ID: 4004483
    [Abstract] [Full Text] [Related]

  • 4. Response to treatment of congenital adrenal hyperplasia in infancy.
    Young MC, Hughes IA.
    Arch Dis Child; 1990 Apr; 65(4):441-4. PubMed ID: 2346339
    [Abstract] [Full Text] [Related]

  • 5. Inappropriate adrenal androgen secretion with once-a-day corticosteroid therapy for congenital adrenal hyperplasia.
    Keenan BS, Eberle AE, Lin TH, Clayton GW.
    J Pediatr; 1990 Jan; 116(1):133-6. PubMed ID: 2153199
    [Abstract] [Full Text] [Related]

  • 6. Daily profiles of salivary cortisol in hydrocortisone treated children with congenital adrenal hyperplasia.
    Hampl R, Foretová L, Sulcová J, Stárka L.
    Eur J Pediatr; 1990 Jan; 149(4):232-4. PubMed ID: 2303071
    [Abstract] [Full Text] [Related]

  • 7. Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia.
    Frisch H, Parth K, Schober E, Swoboda W.
    Arch Dis Child; 1981 Mar; 56(3):208-13. PubMed ID: 7212759
    [Abstract] [Full Text] [Related]

  • 8. [17-hydroxyprogesterone, testosterone and androstenedione in treated congenital adrenogenital syndrome].
    von Schnakenburg K, Bidingmaier F, Knorr D.
    Monatsschr Kinderheilkd (1902); 1977 May; 125(5):579-80. PubMed ID: 876244
    [No Abstract] [Full Text] [Related]

  • 9. [Virilizing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: early diagnosis and response to 2 treatment schedules].
    Cattani A, Mahaha D, Michaud P, Rodríguez JA, López JM, García H, Foradori A, Velásquez CG.
    Rev Chil Pediatr; 1984 May; 55(6):374-9. PubMed ID: 6536989
    [No Abstract] [Full Text] [Related]

  • 10. Dynamics of 24-hour pulsatile cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal patients with nonclassic 21-hydroxylase deficiency and normal prepubertal children.
    Ghizzoni L, Bernasconi S, Virdis R, Vottero A, Ziveri M, Volta C, Iughetti L, Giovannelli G.
    Metabolism; 1994 Mar; 43(3):372-7. PubMed ID: 8139487
    [Abstract] [Full Text] [Related]

  • 11. Plasma progesterone, 17-hydroxyprogesterone, androstenedione and testosterone in prepubertal, pubertal and adult subjects with congenital virilizing adrenal hyperplasia as indicators of adrenal suppression.
    Lee PA, Urban MD, Gutai JP, Migeon CJ.
    Horm Res; 1980 Mar; 13(6):347-57. PubMed ID: 7196877
    [Abstract] [Full Text] [Related]

  • 12. Adrenocortical adenoma associated with inadequately treated congenital adrenal hyperplasia.
    Kurtoğlu S, Atabek ME, Keskin M, Patiroglu TE.
    J Pediatr Endocrinol Metab; 2003 Dec; 16(9):1311-4. PubMed ID: 14714757
    [Abstract] [Full Text] [Related]

  • 13. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ.
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [Abstract] [Full Text] [Related]

  • 14. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?
    Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC.
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4679-85. PubMed ID: 11600525
    [Abstract] [Full Text] [Related]

  • 15. Blood-spot 17-hydroxyprogesterone daily profiles in infants with congenital adrenal hyperplasia.
    Sólyom J, Hosszu E, Gács G.
    Exp Clin Endocrinol; 1990 Sep; 96(1):52-6. PubMed ID: 2279525
    [Abstract] [Full Text] [Related]

  • 16. [Adrenal hyperplasia of late onset: optimization of therapy by measuring the circadian variation of serum 17-OH-progesterone].
    Contreras P, Rojas A, Vega I.
    Rev Med Chil; 1989 Jun; 116(6):552-7. PubMed ID: 2749040
    [Abstract] [Full Text] [Related]

  • 17. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia.
    Silva IN, Kater CE, Cunha CF, Viana MB.
    Arch Dis Child; 1997 Sep; 77(3):214-8. PubMed ID: 9370898
    [Abstract] [Full Text] [Related]

  • 18. Monitoring treatment in congenital adrenal hyperplasia. Use of serial measurements of 17-OH-progesterone in plasma, capillary blood, and saliva.
    Hughes IA, Dyas J, Robinson J, Walker RF, Fahmy DR.
    Ann N Y Acad Sci; 1985 Sep; 458():193-202. PubMed ID: 3879122
    [No Abstract] [Full Text] [Related]

  • 19. Chronopharmacology of hydrocortisone and 9 alpha-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia.
    Moeller H.
    Eur J Pediatr; 1985 Nov; 144(4):370-3. PubMed ID: 4076253
    [Abstract] [Full Text] [Related]

  • 20. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion.
    Pang S, MacGillivray M, Wang M, Jeffries S, Clark A, Rosenthal I, Wiegensberg M, Riddick L.
    J Clin Endocrinol Metab; 1991 Jul; 73(1):166-74. PubMed ID: 2045467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.